AT536173T - Formulations with modified release of at least one form of tramadol - Google Patents

Formulations with modified release of at least one form of tramadol

Info

Publication number
AT536173T
AT536173T AT03743147T AT03743147T AT536173T AT 536173 T AT536173 T AT 536173T AT 03743147 T AT03743147 T AT 03743147T AT 03743147 T AT03743147 T AT 03743147T AT 536173 T AT536173 T AT 536173T
Authority
AT
Austria
Prior art keywords
tramadol
formulations
form
modified release
release
Prior art date
Application number
AT03743147T
Other languages
German (de)
Inventor
Pawan Seth
Paul Maes
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US35785102P priority Critical
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Priority to PCT/US2003/004866 priority patent/WO2003072025A2/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27765948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT536173(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AT536173T publication Critical patent/AT536173T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • A61P29/02Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs) without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
AT03743147T 2002-02-21 2003-02-21 Formulations with modified release of at least one form of tramadol AT536173T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US35785102P true 2002-02-21 2002-02-21
PCT/US2003/004866 WO2003072025A2 (en) 2002-02-21 2003-02-21 Modified release formulations of at least one form of tramadol

Publications (1)

Publication Number Publication Date
AT536173T true AT536173T (en) 2011-12-15

Family

ID=27765948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03743147T AT536173T (en) 2002-02-21 2003-02-21 Formulations with modified release of at least one form of tramadol

Country Status (15)

Country Link
US (4) US7780987B2 (en)
EP (2) EP1476138B8 (en)
JP (3) JP5069395B2 (en)
AT (1) AT536173T (en)
AU (2) AU2003211145B2 (en)
CA (2) CA2476201C (en)
CY (1) CY1112517T1 (en)
DK (1) DK1476138T3 (en)
ES (2) ES2377729T3 (en)
MX (2) MXPA04008164A (en)
NO (1) NO20043913L (en)
NZ (2) NZ535456A (en)
PT (1) PT1476138E (en)
SI (1) SI1476138T1 (en)
WO (2) WO2003072089A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128957B1 (en) * 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
AU2003211145B2 (en) * 2002-02-21 2007-07-12 Valeant International (Barbados) Srl Modified release formulations of at least one form of tramadol
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1905435A3 (en) * 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
WO2005016318A1 (en) * 2003-08-08 2005-02-24 Biovail Laboratories Inc. Modified-release tablet of bupropion hydrochloride
US7206632B2 (en) 2003-10-02 2007-04-17 Medtronic, Inc. Patient sensory response evaluation for neuromodulation efficacy rating
US20050074469A1 (en) * 2003-10-03 2005-04-07 Charles Signorino Stable lipophilic emulsions for acrylic coating and method of making
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084531A1 (en) * 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
US20060099261A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US20060099262A1 (en) * 2004-11-08 2006-05-11 Biokey, Inc. Methods and formulations for making controlled release oral dosage form
US8586085B2 (en) * 2004-11-08 2013-11-19 Biokey, Inc. Methods and formulations for making pharmaceutical compositions containing bupropion
KR101306635B1 (en) 2005-06-27 2013-10-11 밸리언트 인터내셔널(바베이도스) 에스알엘 Modified-release formulations of a bupropion salt
CA2615802C (en) * 2005-07-07 2015-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
EP1940467B1 (en) 2005-09-09 2016-11-02 Paladin Labs Inc. Sustained drug release composition
US8022075B2 (en) * 2005-11-30 2011-09-20 Fujifilm Ri Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
ES2279715B1 (en) * 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. oral formulation of olanzapine.
CN103951667A (en) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 Polymorphs
PE20110235A1 (en) 2006-05-04 2011-04-14 Boehringer Ingelheim Int pharmaceutical combinations comprising metformin and linagliptin
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
CZ300698B6 (en) * 2006-06-16 2009-07-22 Zentiva, A. S. Metformin-containing tablet
US20080031927A1 (en) * 2006-07-11 2008-02-07 Catani Steven J Solid oral dosage vitamin and mineral compositions
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulations comprising a DPP4 inhibitor
AR071375A1 (en) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulations for active pharmaceutical ingredients of poor permeability, preparation process and product
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
CA2638240C (en) 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
UA102429C2 (en) 2009-02-13 2013-07-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Pharmaceutical composition comprising an sglt2 inhibitor, a dppiv inhibitor and a third antidiabetic agent and use thereof
KR20190071840A (en) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
JP2013515783A (en) * 2009-12-29 2013-05-09 インパックス ラボラトリーズ,インコーポレーテッド Gastric retention type solid oral dosage form using swellable hydrophilic polymer
MX341025B (en) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Combination therapy.
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Pharmaceutical compositions containing DPP-4 and / or SGLT-2 and metformin
EP2731947B1 (en) 2011-07-15 2019-01-16 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9532946B2 (en) * 2012-11-20 2017-01-03 Intervet Inc. Manufacturing of semi-plastic pharmaceutical dosage units
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
BR112018072401A2 (en) 2016-06-10 2019-02-19 Boehringer Ingelheim Int of linagliptin and metformin combination
WO2019143744A1 (en) * 2018-01-16 2019-07-25 Applied Materials, Inc. Metal oxide encapsulated drug compositions and methods of preparing the same

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097144A (en) * 1960-10-14 1963-07-09 Upjohn Co Heat-cured, polymeric, medicinal dosage film coatings containing a polyvinylpyrrolidone copolymer, polyethenoid acid, and polyethylene glycol
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
JPS63215620A (en) * 1987-03-03 1988-09-08 Nippon Soda Co Ltd Sustained release preparation
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
JP2700662B2 (en) * 1988-06-22 1998-01-21 大正製薬株式会社 Coated preparation
DE59000232D1 (en) * 1989-02-11 1992-09-10 Bayer Ag Medicinal products with controlled delivery of active substances.
US5292522A (en) * 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
DE69109282T2 (en) 1990-04-11 1995-09-28 Upjohn Co Method for flavoring ibuprofen.
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
EP0804174A4 (en) * 1993-07-21 1998-09-09 Univ Kentucky Res Found A multicompartment hard capsule with control release properties
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19615812A1 (en) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmaceutical preparation containing diphosphonic acids for oral administration
DE19630035A1 (en) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol multiple unit formulations
WO1998027967A1 (en) 1996-12-20 1998-07-02 Dumex-Alpharma A/S Release-controlled coated tablets
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
EP1009387B1 (en) * 1997-07-02 2006-04-12 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
JP4278863B2 (en) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Novel salt and method of metformin
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
DE19826517B4 (en) 1998-06-15 2006-03-23 Baxter Healthcare S.A. Process for the preparation of film-coated tablets with cyclophosphamide as active ingredient and cyclophosphamide film-coated tablet produced therefrom
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
WO2000003696A1 (en) 1998-07-17 2000-01-27 Bristol-Myers Squibb Company Enteric coated pharmaceutical tablet and method of manufacturing
US20030153607A1 (en) 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
DE19901686A1 (en) * 1999-01-18 2000-07-20 Gruenenthal Gmbh Retarded tramadol preparations with a storage-stable release profile and process for their preparation
IN191482B (en) 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
US6183779B1 (en) * 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
DE19940740A1 (en) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmaceutical salts
PT1207866E (en) * 1999-08-31 2005-02-28 Gruenenthal Gmbh Form of delayed administration containing tramadol sacarinate
SK287684B6 (en) * 1999-12-20 2011-06-06 Schering Corporation Sustained release solid oral pharmaceutical dosage composition
US6419956B1 (en) 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
WO2001056544A2 (en) 2000-02-04 2001-08-09 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6676966B1 (en) 2000-05-09 2004-01-13 Intellipharmaceutics Corp. Extended release metformin hydrochloride formulations
IN192159B (en) 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6866866B1 (en) 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
SE0100200D0 (en) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
ITMI20010220A1 (en) 2001-02-05 2002-08-05 Valpharma Sa Multiparticulate formulations for oral administration of lithium salts suitable for a daily administration
US20030157166A1 (en) 2001-03-16 2003-08-21 Chen Chih Ming Controlled release sulfonylurea formulation
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
JP5138856B2 (en) * 2001-06-20 2013-02-06 武田薬品工業株式会社 Tablet manufacturing method
US20040126428A1 (en) 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
ES2295427T3 (en) 2001-09-28 2008-04-16 Mcneil-Ppc, Inc. Dosage forms of modified release.
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20030118647A1 (en) 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
US6667054B2 (en) 2001-12-05 2003-12-23 Bernard Charles Sherman Metformin hydrochloride tablets
TWI252111B (en) 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
SI1355633T1 (en) 2001-12-19 2005-06-30 Astrazeneca Ab NEW FILM COATING containing an ethyl acrylate/methyl methacrylate copolymer and polyvinyl acetate
WO2003055475A1 (en) 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
JP2003290319A (en) * 2002-01-30 2003-10-14 Kikusui Seisakusho Ltd Device for manufacturing tablet
AU2003211145B2 (en) * 2002-02-21 2007-07-12 Valeant International (Barbados) Srl Modified release formulations of at least one form of tramadol
WO2003090723A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US6902746B2 (en) 2002-07-03 2005-06-07 Yung Shin Pharmaceutical Industrial Co., Ltd. Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
SE0202353D0 (en) 2002-08-01 2002-08-01 Astrazeneca Ab New film coating
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US7018658B2 (en) 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
DE10260919A1 (en) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Process for the preparation of coated dosage forms and dietary supplements with concentration gradients in the coating
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20050048118A1 (en) 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
US20050025829A1 (en) 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
US20050123596A1 (en) 2003-09-23 2005-06-09 Kohane Daniel S. pH-triggered microparticles
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
US20050084531A1 (en) 2003-10-16 2005-04-21 Jatin Desai Tablet with aqueous-based sustained release coating
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
KR101306635B1 (en) * 2005-06-27 2013-10-11 밸리언트 인터내셔널(바베이도스) 에스알엘 Modified-release formulations of a bupropion salt

Also Published As

Publication number Publication date
CA2476496C (en) 2009-12-15
US20130245154A1 (en) 2013-09-19
EP1476138A2 (en) 2004-11-17
AU2003211145B2 (en) 2007-07-12
ES2377729T3 (en) 2012-03-30
DK1476138T3 (en) 2012-02-20
MXPA04008164A (en) 2005-05-17
PT1476138E (en) 2012-02-14
EP1476139B1 (en) 2017-05-17
US20150030675A1 (en) 2015-01-29
US20040037883A1 (en) 2004-02-26
CA2476201C (en) 2009-09-01
EP1476138A4 (en) 2008-05-07
CA2476201A1 (en) 2003-09-04
AU2003211146A1 (en) 2003-09-09
JP2010155864A (en) 2010-07-15
NZ535455A (en) 2009-08-28
EP1476138B1 (en) 2011-12-07
JP2005526043A (en) 2005-09-02
WO2003072025A2 (en) 2003-09-04
WO2003072089A1 (en) 2003-09-04
US7780987B2 (en) 2010-08-24
NO20043913L (en) 2004-11-16
SI1476138T1 (en) 2012-07-31
AU2003211146B2 (en) 2007-07-19
JP2005526047A (en) 2005-09-02
JP4704685B2 (en) 2011-06-15
CY1112517T1 (en) 2015-12-09
CA2476496A1 (en) 2003-09-04
EP1476139A4 (en) 2007-12-26
EP1476138B8 (en) 2012-03-07
EP1476139A1 (en) 2004-11-17
JP5069395B2 (en) 2012-11-07
MXPA04008100A (en) 2005-06-17
ES2627842T3 (en) 2017-07-31
AU2003211145A1 (en) 2003-09-09
WO2003072025A3 (en) 2003-11-06
US20080274177A1 (en) 2008-11-06
NZ535456A (en) 2006-08-31

Similar Documents

Publication Publication Date Title
DE60335815D1 (en) Hardening composition
DE60223269D1 (en) Pharmaceutical forms for modified release
DE60327940D1 (en) Listen-talk set
DE60221900D1 (en) Film-composing compositions and their use
DE60318372D1 (en) Shoe
DE60332026D1 (en) Ubstituated alpha-ketoic acid
DK1474117T3 (en) Composition of inhalation
DE60336213D1 (en) Surgical clawer
DK1553929T3 (en) Controlled release composition.
DE60238156D1 (en) Two-way curable silicone compositions
DE50303531D1 (en) Lace
DE60333311D1 (en) Cosmetic composition
DE60329800D1 (en) Actuator of constant force
DK1543065T3 (en) biomedical compositions
DE60325511D1 (en) Depot formulations with delayed release
AT327863T (en) Getriebegehäuse
AT311804T (en) Blowermotor
DE60308997D1 (en) Formulations for inhalation
DE60313164D1 (en) Allylsilane-containing composition
DE50304983D1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinaseinhibitors
DE60330694D1 (en) Pyrimidopyrimidone as kinaseinhibitors
FI20021638A0 (en) handover
DE60322340D1 (en) fragrance CONNECTION
DK1390066T3 (en) vaccine Composition
AT529094T (en) Composition for external application